CD4 cell count-guided treatment interruption: Be smart and wait for more evidence

Clinical Infectious Diseases

Volumn 40, Issue 5, 2005, Pages 735-737

  Arduino, Roberto C ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE;

CLINICAL ARTICLE; DRUG HALF LIFE; EDITORIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; LEUKOCYTE COUNT; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS;

EID: 15044356845     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/427885     Document Type: Editorial

References (15)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
2. The Data Collection on Adverse Events of Anti-HIV Drugs Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
3. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30:471-7.
4. Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Suter F. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. AIDS 2004; 18:439-46.
5. + T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies. J Infect Dis 2002; 186:851-4.
6. Schweighardt B, Ortiz GM, Grant RM, et al. Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. AIDS 2002; 16:2342-4.
7. Martinez-Picado J, Morales-Lopetegi K, Wrin T, et al. Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS 2002; 16:895-9.
8. Nuesch R, Ananworanich J, Sirivichayakul S, et al. Development of resistance after CD4-guided structured treatment interruptions in HIV-infected patients treated with highly active antiretroviral therapy after dual-nucleoside treatment. Clin Infect Dis 2005; 40:728-34 (in this issue).
9. Lawrence J, Mayers DL, Hullsiek KH, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003; 349:837-46.
10. Metzner KJ, Bonhoeffer S, Fischer M, et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 2003; 188:1433-43.
11. Dybul M, Chun TW, Yoder C, et al. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci USA 2001; 98:15161-6.
12. Dybul M, Nies-Kraske E, Daucher M, et al. Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters. J Infect Dis 2003; 188:388-96.
13. Yerly S, Fagard C, Gunthard HF, Hirschel B, Perrin L; Swiss HIV Cohort Study. Drug resistance mutations during structured treatment interruptions. Antivir Ther 2003; 8:411-5.
14. Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000; 356:291-6.
15. The PLATO Collaboration. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364:51-62.